Drugs / GAD-Alum
GAD-Alum
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02352974 | Jan 2015 → Oct 2019 | type 1 diabetes mellitus | Johnny Ludvigsson | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05351879 | May 2022 → Aug 2023 | type 1 diabetes mellitus | Linkoeping University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05683990 | Jul 2024 → Mar 2028 expected | type 1 diabetes mellitus | Diamyd Medical AB | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02387164 | Mar 2015 → Oct 2019 | prediabetes syndrome, type 1 diabetes mellitus | Lund University | Terminated | No outcome recorded |
| Phase 2 | NCT01129232 | Jan 2011 → Jan 2013 | enterovirus infectious disease, immune dysregulation, autoimmunity, and autoinflammation, type 1 diabetes mellitus | Oslo University Hospital | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01785108 Comparator | Feb 2013 → Mar 2017 | type 1 diabetes mellitus | Johnny Ludvigsson | Completed | No outcome recorded |
| Phase 2 | NCT01122446 Comparator | Apr 2009 → Dec 2016 | prediabetes syndrome, type 1 diabetes mellitus | Lund University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAD-Alum | “We investigated if autoantigen-specific treatment with alum-formulated glutamate decarboxylase (GAD-Alum) was safe and affected progression to type 1 diabetes in children with...” PMID 29171140 ↗ Nov 2017 |
| Known as | Alum-GAD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02387164 ↗ |
| Known as | Diamyd | “GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals” NCT02352974 ↗ |
| Known as | glutamic acid decarboxylase (GAD)-alum | “AIM: Double-blind placebo-controlled intervention using glutamic acid decarboxylase (GAD)-alum, vitamin D and Ibuprofen in recent onset Type I diabetes (T1D).” PMID 32802401 ↗ Jun 2020 |
| Modality | Protein / enzyme biologic | “autoantigen-specific treatment with alum-formulated glutamate decarboxylase (GAD-Alum)” PMID 29171140 ↗ Nov 2017 |
| Route | Subcutaneous | “GAD-Alum as a subcutaneous prime and boost injection” PMID 29171140 ↗ Nov 2017 |